© 1997 American Heart Association, Inc.
Articles |
Effects of Short-term Hormone Replacement Therapies on Low-Density Lipoprotein Metabolism in Cynomolgus Monkeys
From the Comparative Medicine Clinical Research Center (J.D.W., L.Z., M.R.A.) and the Departments of Pathology (D.C.S.) and Internal Medicine (D.A.-B.), Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC; and Rush-Presbyterian–St Luke's Medical Center (J.D.B.), Chicago, Ill.
Abstract Estrogen replacement therapy reduces the risk of coronary heart disease in women and decreases the extent of atherosclerosis in monkeys. In our previous studies, estrogen treatment decreased arterial LDL degradation and accumulation, thus indicating one mechanism by which estrogen inhibits the progression of atherosclerosis. The influence of progestins on these processes remains unclear. The objective of this study was to determine the effects of oral estrogen (conjugated equine estrogens) and progestin (medroxyprogesterone acetate) alone or in combination on arterial LDL metabolism after 12 weeks of atherogenic stimulus. This relatively short period of treatment was chosen to determine effects on arterial LDL metabolism before substantial subendothelial macrophage accumulation. In contrast to previous studies (16 to 18 weeks of treatment), when macrophages were present in the intima, neither estrogen nor progestin (nor their combination) had any effect on any index of arterial LDL metabolism. These results suggest that estrogen may preferentially reduce LDL metabolism in macrophages with little effect on cells of the normal artery. In contrast to arterial LDL metabolism, hepatic LDL uptake was significantly increased in animals treated with estrogen or estrogen plus progestin. Despite the increased LDL uptake by the liver, hepatic lipid content was significantly decreased by 
50% in both estrogen and estrogen-plus-progestin treatment compared with control and progestin-treated animals. The decrease in hepatic cholesterol content is hypothesized to be due to increased biliary secretion of cholesterol.
Key Words: cholesterol • cynomolgus monkeys • liver • estrogen • LDL metabolism • progestin
This article has been cited by other articles:
 |
|
 |
|
  J. B. Hodgin and N. Maeda Minireview: Estrogen and Mouse Models of Atherosclerosis Endocrinology, December 1, 2002; 143(12): 4495 - 4501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Mullick, B. A. Walsh, K. M. Reiser, and J. C. Rutledge Chronic estradiol treatment attenuates stiffening, glycoxidation, and permeability in rat carotid arteries Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H2204 - H2210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Dubey and E. K. Jackson Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms Am J Physiol Renal Physiol, March 1, 2001; 280(3): F365 - F388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Albert, M. Vallée, G. Beaudry, A. Bélanger, and D. W. Hum The Monkey and Human Uridine Diphosphate-Glucuronosyltransferase UGT1A9, Expressed in Steroid Target Tissues, Are Estrogen-Conjugating Enzymes Endocrinology, July 1, 1999; 140(7): 3292 - 3302. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. C. Schwenke, J. D. Wagner, and M. R. Adams In vitro lipid peroxidation of LDL from postmenopausal cynomolgus macaques treated with female hormones J. Lipid Res., February 1, 1999; 40(2): 235 - 244. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. E. Gallagher, P. Li, J. R. Lenhart, M. C. Chappell, and K. B. Brosnihan Estrogen Regulation of Angiotensin-Converting Enzyme mRNA Hypertension, January 1, 1999; 33(1): 323 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Wagner, M. J. Thomas, J. K. Williams, L. Zhang, K. A. Greaves, and W. T. Cefalu Insulin Sensitivity and Cardiovascular Risk Factors in Ovariectomized Monkeys with Estradiol Alone or Combined with Nomegestrol Acetate J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 896 - 901. [Abstract] [Full Text]
|
|